SAN DIEGO, Aug. 06, 2019 (GLOBE NEWSWIRE) — Obalon Therapeutics Inc. (Nasdaq: OBLN) (the ?Company?), a vertically integrated medical technology company with the first and only FDA-approved swallowable, gas-filled intragastric balloon system for the treatment of obesity, today announced the closing of its previously announced underwritten public offering of (i) 2,015,000 shares of common stock together with common stock purchase warrants (the ?purchase warrants?) to purchase 1,511,250 shares of common stock, (ii) 1,735,000 pre-funded warrants, with each pre-funded warrant exercisable for one share of common stock, together with common warrants to purchase 1,301,250 shares of common stock and (iii) 412,500 shares of common stock and 421,875 purchase warrants pursuant to the over-allotment option. The shares of common stock and accompanying purchase warrants were sold together at a combined public offering price of $4.00 per share, and the pre-funded
Related Articles

Obalon Announces First Quarter 2020 Financial Results and Business Update
SAN DIEGO, June 19, 2020 (GLOBE NEWSWIRE) — Obalon Therapeutics, Inc. (Nasdaq: OBLN), a weight loss solutions company with the first and only FDA-approved swallowable, gas-filled intragastric balloon system for the treatment of obesity, today announ… […]

Obalon Announces First Patient Treatments at its First Company-Owned Center for Weight Loss
SAN DIEGO, Oct. 22, 2019 (GLOBE NEWSWIRE) — Obalon Therapeutics, Inc. (NASDAQ:OBLN), a?weight loss solutions company with the first and only?FDA-approved swallowable, gas-filled intra-gastric balloon for non-surgical weight loss,?announces it has tr… […]

Obalon To Present at Two Upcoming Institutional Investor Conferences
SAN DIEGO, Nov. 14, 2019 (GLOBE NEWSWIRE) — Obalon Therapeutics, Inc. (NASDAQ: OBLN), a?weight loss solutions company focused on commercializing the Obalon Balloon System, the first and only?FDA-approved swallowable, gas-filled intra-gastric balloon… […]